Emergent BioSolutions (EBS) Misses Q1 EPS by 22c, Offers Guidance

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.13), $0.22 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $190.6 million versus the consensus estimate of $201.16 million.

GUIDANCE:

Emergent BioSolutions sees Q2 2019 revenue of $200-220 million, versus the consensus of $254.14 million.

Emergent BioSolutions sees FY2019 revenue of $1.06-1.14 billion, versus the consensus of $1.08 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Ennis (EBF) Reports In-Line Q1 EPS